Literature DB >> 25304786

RTOG 9003: legacies of a landmark trial.

Andy Trotti1, Mitchell Machtay2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25304786      PMCID： PMC5823512          DOI： 10.1016/j.ijrobp.2014.07.022

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  9 in total

1.  Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer.

Authors:  Heather E Newlin; Robert J Amdur; Charles E Riggs; Christopher G Morris; Jessica M Kirwan; William M Mendenhall
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

2.  [Claudius Regaud (1870-1940): A pioneer of radiobiology and radiotherapy].

Authors:  N Foray
Journal:  Cancer Radiother       Date:  2012-07-19       Impact factor: 1.018

3.  RTOG 9003: the untold story.

Authors:  Steven Feigenberg; Kruti Patel; Robert J Amdur; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-10-01       Impact factor: 7.038

4.  Hyperfractionated photon radiation therapy in the treatment of advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses, using radiation therapy as the only planned modality: (preliminary report) by the Radiation Therapy Oncology Group (RTOG).

Authors:  V A Marcial; T F Pajak; C Chang; L Tupchong; J Stetz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-01       Impact factor: 7.038

Review 5.  Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis.

Authors:  Jean Bourhis; Jens Overgaard; Hélène Audry; Kian K Ang; Michele Saunders; Jacques Bernier; Jean-Claude Horiot; Aurélie Le Maître; Thomas F Pajak; Michael G Poulsen; Brian O'Sullivan; Werner Dobrowsky; Andrzej Hliniak; Krzysztof Skladowski; John H Hay; Luiz H J Pinto; Carlo Fallai; Karen K Fu; Richard Sylvester; Jean-Pierre Pignon
Journal:  Lancet       Date:  2006-09-02       Impact factor: 79.321

6.  T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy.

Authors:  Bhishamjit S Chera; Robert J Amdur; Christopher G Morris; Jessica M Kirwan; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-12       Impact factor: 7.038

7.  Dose-response for local control with hyperfractionated radiation therapy in advanced carcinomas of the upper aerodigestive tracts: preliminary report of radiation therapy oncology group protocol 83-13.

Authors:  J D Cox; T F Pajak; V A Marcial; G E Hanks; M Mohiuddin; K K Fu; R W Byhardt; P Rubin
Journal:  Int J Radiat Oncol Biol Phys       Date:  1990-03       Impact factor: 7.038

8.  Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial.

Authors:  Jens Overgaard; Hanne Sand Hansen; Lena Specht; Marie Overgaard; Cai Grau; Elo Andersen; Jens Bentzen; Lars Bastholt; Olfred Hansen; Jørgen Johansen; Lisbeth Andersen; Jan F Evensen
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

9.  Randomized trial of hyperfractionation versus conventional fractionation in T2 squamous cell carcinoma of the vocal cord (RTOG 9512).

Authors:  Andy Trotti; Qiang Zhang; Søren M Bentzen; Bahman Emami; M Elizabeth Hammond; Christopher U Jones; William H Morrison; Stephen M Sagar; John A Ridge; Karen K Fu; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-08       Impact factor: 7.038
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.